GBA Presents: RADIO SAVANT-!

The HF does boring ass shit like buy Insurance names... I can't do it but they are going up.
This one is taking Twitter's place in S&P

ACGL Arch Capital Group Ltd.

$51.692.90(+5.94%)4:00 PM 10/27/22
NASDAQ |$USD |Pre-Market:$54.80+3.11(+6.02%)7:27 AM


JinkoSolar Holding GAAP EPADS of $0.90 beats by $0.38, revenue of $2.74B beats by $140M
Oct. 28, 2022 7:19 AM ET JinkoSolar Holding Co., Ltd. (JKS)
  • JinkoSolar Holdingpress release(NYSE:JKS): Q3 GAAP EPADS of $0.90beats by $0.38.
  • Revenue of $2.74B (+106.0% Y/Y)beats by $140M.
  • Gross margin was 15.7%, compared with 14.7% in Q2 2022 and 15.1% in Q3 2021.
  • "We see strong demand growth in the global market and expect module shipments to be in the range of 13.0 GW to 15.0 GW for the fourth quarter and 41.5 GW to 43.5 GW for full year 2022. "
 
All these ole' reliable names are doing well-- (except Clorox has a big recall on pine Sol)

Church & Dwight tops estimates, points to strong consumption trends
Oct. 28, 2022 7:33 AM ET Church & Dwight Co., Inc. (CHD)



image_458639953.jpg
 
Trulieve Cannabis assumed with a Buy at BTIG 08:17 TCNNF BTIG analyst Jonathan DeCourcey assumed coverage of Trulieve Cannabis with a Buy rating and C$26 price target as part of a broader research note expanding coverage of the Cannabis industry. The analyst states that further upside for Trulieve will come with greater clarity on Florida's hurricane impact as well as the anticipated timing of potential Connecticut and Pennsylvania recreational cannabis launches. These represent near term catalysts for Trulieve results and particularly will be showcase opportunities for the company to expand beyond the legacy Florida business, DeCourcey adds.
 
Curaleaf assumed with a Buy at BTIG 08:15 CURLF BTIG analyst Jonathan DeCourcey assumed coverage of Curaleaf with a Buy rating and C$10 price target. Curaleaf is the largest multi-state operator in U.S. cannabis and is "poised to benefit from that standing," DeCourcey tells investors in a research note. The analyst says Curaleaf has an established presence in every U.S. state market that does or will matter in the near term while recently having developed an early presence in potential large scale European markets "that could one day offer significant growth."

AbbVie reports Q3 adjusted EPS $3.66, consensus $3.57 » 07:44 ABBV Reports Q3 revenue…

Terex raises 2022 EPS view to $4.00-$4.20 from $3.80-$4.20, consensus $3.96 16:21 TEX Narrows 2022 revenue view to $4.3B from $4.1B-$4.3B, consensus $4.22B.
 
FirstCash sees 'significant' y/y revenue, earnings growth in 2022 15:59 FCFS FirstCash said earlier: The Company outlook for 2022 remains very positive as it continues to expect significant year-over-year revenue and earnings growth based on the first nine-months results and current trends. Anticipated conditions and trends for the remainder of the year include the following: Pawn operations are expected to remain the primary earnings driver for 2022 as the Company expects segment income from the combined U.S. and Latin America pawn segments will be approximately 80% of total adjusted segment level pre-tax income. October retail sales results continue to be strong as well, with month-to-date same-store sales up 7% in the U.S. and over 10% in Latin America over the comparative prior-year period. The Company continues to expect up to 60 new store additions in 2022 through a combination of de novo openings and acquisitions.
 
You must log in or register to reply here.
Back
Top